key: cord-0830419-4oks1aku
authors: Bennani, N.N.; Bennani-Baiti, I.M.
title: Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients
date: 2020-08-18
journal: Ann Oncol
DOI: 10.1016/j.annonc.2020.08.2095
sha: 62f82f1653655adae23d0e0f1a8942c9726cacd4
doc_id: 830419
cord_uid: 4oks1aku

nan

.

Several findings indicate that TMPRSS2 is unlikely to play a major role in SARS-CoV-2 lung pathology in men (and . Nevertheless, if one were to assume that the fatality rates of the control group sans ADT (~ 16%) are similar to those of the ADT group, one would predict less than 1 death in the latter, a finding consistent with the lack of fatalities in this group.

Androgen-deprivation therapies for prostate cancer and risk of 65 infection by SARS-CoV-2: a population-based study (n=4532)

No evidence that androgen regulation of pulmonary TMPRSS2 explains 70 sex-discordant COVID-19 outcomes

Androgen receptor and androgen-dependent gene expression in 72 lung

required for SARS-CoV-2 entry, is downregulated in lung cells by 74 enzalutamide, a prostate cancer therapeutic

What does androgenetic alopecia have to do with COVID-19? An insight 76 into a potential new therapy

Androgen receptor targeted therapy sensitizes tumor bearing mice to